A 2025 ACC Scientific Statement highlighted the positive impact of anti-obesity medications on patients with heart failure with preserved ejection fraction (HFpEF) and obesity. Clinical trial findings demonstrated significant weight reduction and improvements in functional capacity with semaglutide and tirzepatide. There are diagnostic challenges in assessing obesity in HFpEF patients, and structured monitoring is advised during the initiation of anti-obesity medications. Metabolic and bariatric surgery was discussed as a treatment option, but potential risks were noted. Evidence-based selection criteria for FDA-approved anti-obesity therapies were provided, indicating potential improvements in quality of life and reductions in HF events.

Source: Journal of the American College of Cardiology